Ann Richmond

Dr. Ann Richmond

Vanderbilt University Medical Center, Vanderbilt University School of Medicine, Nashville, TN, USA
orcid

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Cancer Cell
Verified
Journal Article
Closed access
LYLi Yang
Li Yang
JHJianhua Huang
Jianhua Huang
XRXiubao Ren
Xiubao Ren
AGAgnieszka E. Gorska
Agnieszka E. Gorska
ACAnna Chytil
Anna Chytil
HMHarold L. Moses
Harold L. Moses

1 March 2010 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
GLGwendal Lazennec
Gwendal Lazennec
ARAnn Richmond
Ann Richmond

1 November 2000 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
CAChristina L. Addison
Christina L. Addison
TDThomas O Daniel
Thomas O Daniel
MBMarie D. Burdick
Marie D. Burdick
HLHua Liu
Hua Liu
JEJan E Ehlert
Jan E Ehlert
RSRobert M. Strieter
Robert M. Strieter
We have previously shown that members of the ELR+ CXC chemokine family, including IL-8; growth-related oncogenes α, β, and γ; granulocyte chemotactic protein 2; and epithelial neutrophil-activating protein-78, can mediate angiogenesis in the absence of preceding inflammation. To date, the receptor on endothelial cells responsible for chemotaxis and neovascularization mediated by these ELR+ CXC chemokines has not been determined. Because all ELR+ CXC chemokines bind to CXC chemokine receptor 2 (CXCR2), we hypothesized that CXCR2 is the putative receptor for ELR+ CXC chemokine-mediated angiogenesis. To test this postulate, we first determined whether cultured human microvascular endothelial cells expressed CXCR2. CXCR2 was detected in human microvascular endothelial cells at the protein level by both Western blot analysis and immunohistochemistry using polyclonal Abs specific for human CXCR2. To determine whether CXCR2 played a functional role in angiogenesis, we determined whether this receptor was involved in endothelial cell chemotaxis. We found that microvascular endothelial cell chemotaxis in response to ELR+ CXC chemokines was inhibited by anti-CXCR2 Abs. In addition, endothelial cell chemotaxis in response to ELR+ CXC chemokines was sensitive to pertussis toxin, suggesting a role for G protein-linked receptor mechanisms in this biological response. The importance of CXCR2 in mediating ELR+ CXC chemokine-induced angiogenesis in vivo was also demonstrated by the lack of angiogenic activity induced by ELR+ CXC chemokines in the presence of neutralizing Abs to CXCR2 in the rat corneal micropocket assay, or in the corneas of CXCR2−/− mice. We thus conclude that CXCR2 is the receptor responsible for ELR+ CXC chemokine-mediated angiogenesis.

1 October 2007 in Cancer Letters
Verified
Journal Article
Closed access
DRDayanidhi Raman
Dayanidhi Raman
PBPaige J. Baugher
Paige J. Baugher
YTYee Mon Thu
Yee Mon Thu
ARAnn Richmond
Ann Richmond

1 September 2002 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
ARAnn Richmond
Ann Richmond

26 September 2008 in Disease Models & Mechanisms
Verified
Journal Article
Closed access
PDF file
ARAnn Richmond
Ann Richmond
YSYingjun Su
Yingjun Su
> If one wants to know whether a patient’s tumor will respond to a specific therapeutic regime, one must examine the response of that human tumor, not a mouse tumor, to the therapy Numerous murine models have been developed to study human cancer. These models are used to investigate the factors